Seminars in Oncology
Volume 34, Issue 4 , Pages 295-302 , August 2007

Strategies for Screening for Pancreatic Adenocarcinoma in High-Risk Patients

  • Marcia Irene Canto

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marcia Irene Canto, MD, MHS, Johns Hopkins University Division of Gastroenterology, The Sol Goldman Pancreatic Cancer Research Center, 1830 E Monument St, Room 425, Baltimore, MD 21205.

References 

  1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427
  2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas (201 patients). Ann Surg. 1995;221:721–731
  3. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg. 2004;198:722–731
  4. Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma (A collective study). Cancer. 1996;78:986–990
  5. Maitra A, Fukushima N, Takaori K, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005;12:81–91
  6. Hruban H. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–987
  7. Hruban RH, Wilentz RE, Goggins M, et al. Pathology of incipient pancreatic cancer. Ann Oncol. 1999;10:9–11
  8. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2006;6:2969–2972
  9. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002–2006
  10. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2005;6:17–32
  11. Adsay NV, Basturk O, Cheng JD, et al. Ductal neoplasia of the pancreas: Nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol. 2005;15:254–264
  12. Kawamoto S, Horton KM, Lawler LP, et al. Intraductal papillary mucinous neoplasm of the pancreas: Can benign lesions be differentiated from malignant lesions with multidetector CT?. Radiographics. 2005;25:1451–1468
  13. Wiesenauer CA, Schmidt CM, Cummings OW, et al. Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms. Arch Surg. 2003;138:610–617
  14. Suzuki Y, Atomi Y, Sugiyama M, et al. Cystic neoplasm of the pancreas: A Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas. 2004;28:241–246
  15. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. International Hereditary Pancreatitis Study Group Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst. 1997;89:442–446
  16. Lowenfels AB, Maisonneuve P, Whitcomb DC International Hereditary Pancreatitis Study Group. Risk factors for cancer in hereditary pancreatitis. Med Clin North Am. 2000;84:565–573
  17. Whitcomb DC, Ulrich CD. Hereditary pancreatitis: New insights, new directions. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:253–263
  18. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209–3215
  19. Gruber SB, Entius MM, Petersen GM, et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res. 1998;58:5267–5270
  20. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447–1453
  21. Cancer risks in BRCA2 mutation carriers (The Breast Cancer Linkage Consortium). J Natl Cancer Inst. 1999;91:1310–1316
  22. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364
  23. Swift M, Sholman L, Perry M, et al. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res. 1976;36:209–215
  24. Geoffroy-Perez B, Janin N, Ossian K, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer. 2001;93:288–293
  25. Ghadirian P, Boyle P, Simard A, et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol. 1991;10:183–196
  26. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–2638
  27. Rulyak SJ, Lowenfels AB, Maisonneuve P, et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124:1292–1299
  28. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res. 2001;7:738–744
  29. Bartsch DK, Kress R, Sina-Frey M, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer. 2004;110:902–906
  30. Klein AP, Beaty TH, Bailey-Wilson JE, et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol. 2002;23:133–149
  31. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2006;15:704–710
  32. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res. 2002;62:3789–3793
  33. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95:214–221
  34. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:342–346
  35. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006;3:e516
  36. McFaul CD, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut. 2006;55:252–258
  37. Peters JA, Stopfer JE. Role of the genetic counselor in familial cancer. Oncology. 1996;10:159–166(Williston Park)
  38. American Gastroenterological Association medical position statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117:1463–1484
  39. Agarwal B, Abu-Hamda E, Molke KL, et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol. 2004;99:844–850
  40. Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 1998;170:1315–1322
  41. DeWitt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 2004;141:753–763
  42. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–781
  43. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: An EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–621
  44. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am. 2000;84:707–718
  45. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247–255
  46. Emerson RE, Randolph ML, Cramer HM. Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of intraductal papillary mucinous neoplasm of the pancreas is highly predictive of pancreatic neoplasia. Diagn Cytopathol. 2006;34:457–462
  47. Brune K, Abe T, Canto M, O’Malley L, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–1076
  48. Catalano MF, Lahoti S, Geenen JE, et al. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc. 1998;48:11–17
  49. Sahai AV, Zimmerman M, Aabakken L, et al. Prospective assessment of the ability of endoscopic ultrasound to diagnose, exclude, or establish the severity of chronic pancreatitis found by endoscopic retrograde cholangiopancreatography. Gastrointest Endosc. 1998;48:18–25
  50. Wiersema MJ, Hawes RH, Lehman GA, et al. Prospective evaluation of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in patients with chronic abdominal pain of suspected pancreatic origin. Endoscopy. 1993;25:555–564
  51. Hollerbach S, Klamann A, Topalidis T, et al. Endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA) cytology for diagnosis of chronic pancreatitis. Endoscopy. 2001;33:824–831
  52. Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182–186
  53. Watanabe H, Ha A, Hu YX, et al. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer. 1999;86:1441–1448
  54. Ohuchida K, Mizumoto K, Ogura Y, et al. Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer. Clin Cancer Res. 2005;11:2285–2292
  55. Trumper L, Menges M, Daus H, et al. Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: A multicenter prospective trial. J Clin Oncol. 2002;20:4331–4337
  56. Uno K, Azuma T, Nakajima M, et al. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2000;15:1333–1338
  57. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006;66:1208–1217
  58. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868–1875
  59. Poley JA, Wagner A, Kuipers EJ. Endoscopic ultrasonography: A valuable tool in screening high-risk patients for pancreatic cancer. Gastroenterology. 2007;132:A-690;(abstr)
  60. Kurtz RC, Simon J, Ludwig E, et al. A pancreatic cancer screening program for familial high-risk individuals. Gastroenterology. 2007;132:A-199;(abstr)
  61. Latchford A, Greenhalf W, Vitone LJ, et al. Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg. 2006;93:1446–1455

PII: S0093-7754(07)00113-3

doi: 10.1053/j.seminoncol.2007.05.008

Seminars in Oncology
Volume 34, Issue 4 , Pages 295-302 , August 2007

Article Tools